TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

MS pain is the uninvited guest you can't turn away, columnist Desiree Lama writes. Listening to your body is the key to ...

Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...

In people with early MS, diet may correlate with biological aging and the development of disease-related disability, study ...

Scientists at the 2026 ACTRIMS forum meet to assess current approaches and explore new directions for MS research and care.

Teva Canada and Novartis Canada are collaborating to ensure continued access to Mayzent for people with active SPMS in Canada ...

After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...

When an insurance denial blocks guest writer Denise Schnieders from getting an MS disease activity test, she decides to fight back.

BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...

A small study suggests Mavenclad’s effectiveness in MS may be linked to how regulatory T-cells respond to treatment.

Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...